(19)

(11)

EP 4 499 066 A1

(12)

(43) Date of publication: 05.02.2025 Bulletin 2025/06 (21) Application number: 23781540.2 (22) Date of filing: 02.02.2023

(51) International Patent Classification (IPC):  A61K 31/36(2006.01) A61K 31/137(2006.01) C07D 317/48(2006.01) A61P 25/24(2006.01) A61P 25/26(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/36; A61P 25/26; A61K 45/06; A61K 31/138   C-Sets: A61K 31/36, A61K 2300/00; A61K 31/138, A61K 2300/00; (86) International application number: PCT/US2023/012196 (87) International publication number: WO 2023/191952 (05.10.2023 Gazette 2023/40)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 31.03.2022 US 202263325757 P 07.04.2022 US 202263328343 P 01.08.2022 WO PCT/US2022/074369 04.01.2023 US 202363437000 P (71) Applicant: Transcend Therapeutics, Inc. New York, NY 10011 (US)

(72) Inventors: MANDELL, Blake Brooklyn, New York 11215 (US) STOGNIEW, Martin Lakewood Ranch, Florida 34202 (US) SCHMIDT, Jennifer Louise Garden City, New York 11530 (US) SEELIG, Markus Kelseyville, California 95451 (US) (74) Representative: Pearl Cohen Zedek Latzer Baratz UK LLP  The Gridiron Building One Pancras Square London N1C 4AG London N1C 4AG (GB)